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Abstract 
Age-related macular degeneration (AMD) is a major cause of blindness worldwide. Currently, 1.75 million 
people are affected by advanced AMD, and with ageing population 3 million people will be affected by 
2020 in many countries. At present, 7 million people are at risk of developing advanced AMD, and 1 in 3 
persons aged 70 or older with early AMD will develop advanced disease over 10 years. The devastating 
impact to both the individual and general public is staggering. No effective preventive drug therapies exist 
although nutritional and behavioral modifications can reduce progression to advanced age-related macular 
degeneration. Application of vascular endothelial growth factor inhibitors through intraocular injections 
represents a treatment option only for selected types of AMD and is related with short-term efficacy, 
required re-treatments and ocular and systemic side effects. There is a need for new drugs taken in a 
non-invasive way. A growing body of the literature indicates the involvement of lipids and lipoproteins in 
the formation of AMD lesions. The most commonly used lipid lowering drugs are statins with a strong 
efficacy record in reducing cholesterol. The goal of this review is to evaluate the effectiveness of these 
drugs as an alternative therapy in AMD. Improving treatments that reverse, prevent, or even delay the onset 
of AMD would have significant benefit to both the individual and society.      
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1. Introduction 
Age-related macular degeneration (AMD) is a major cause of blindness worldwide (Evans, (2001). 
Currently, 1.75 million people are affected by advanced AMD, and with ageing population 3 million people 
will be affected by 2020 in many countries. At present, 7 million people are at risk of developing advanced 
AMD, and 1 in 3 persons aged 70 or older with early AMD will develop advanced disease over 10 years 
(Mukesh et al., 2004). The devastating impact to both the individual and general public is staggering. In 
Canada and Australia, the financial impact is estimated to be $2.6 billion on the gross domestic product 
(Brown et al., 2005; Centre of Eye Research Australia, 2006).  The continued trend for increased life 
expectancy predicts a doubling in the number of people with AMD with costs reaching $59 billion over the 
next 20 years (Centre of Eye Research Australia ).   Since 2000, the number of people age 50 and older 
with late age-related macular degeneration (AMD) has climbed by 25 percent, to 2,069,403.This startling 
increase was documented in "Vision Problems in the U.S.," a report released by Prevent Blindness America 
and the National Eye Institute and compiled by researchers from Johns Hopkins University. 
Improving treatments that reverse, prevent, or even delay the onset of AMD would have significant benefit 
to both the individual and society.  
Age-related macular degeneration is typically classified into two clinical forms, no exudative or “dry” and 
exudative or “wet”, both of which can lead to visual loss. In the dry or no exudative form, visual loss is 
usually gradual. The hallmark changes that are seen in the macula are yellow subretinal deposits called 
drusen, or retinal pigment epithelium (RPE) hyperpigmentary or hypopigmentary irregularities. Drusen 
may enlarge and become confluent, and even evolve into drusenoid RPE detachments, where the RPE 
becomes separated from its underlying Bruch’s membrane. These drusenoid detachments often progress to 
geographic atrophy, where the RPE dies from apoptosis or into wet AMD. In the wet form, also called 
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exudative or neovascular AMD, vision loss can occur suddenly when a choroidal neovascular membrane 
develops in the sub-RPE, between the RPE and Bruch’s membrane, and it subretinal space, between the 
neurosensory retina and RPE, and it leaks fluid or blood (Ryan, 2006). Major risk factors include cigarette 
smoking, nutritional factors, cardiovascular diseases, and genetic markers, including genes regulating 
complement, lipid, angiogenic, and extracellular matrix pathways (Lim et al., 2012). 
No effective preventive drug therapies exist although nutritional and behavioral modifications can reduce 
progression to advanced age-related macular degeneration. Current treatment options by endothelial growth 
factor (VEGF) inhibitors – anti-VEGF therapy are limited to the late stage of the disease, when central 
vision is already under great threat, and even new treatments make little impact on the rate of blindness. 
Monthly intravitreal anti-VEGF injections with systemic exposure to anti-VEGF will be replaced by new 
drugs taken in a non-invasive way. There is no effective treatment for AMD or for arresting its progression 
in its earliest phases. 
Overlapping in risk factors for AMD and cardiovascular disease had led some to suggest that the 
pathophysiology of these diseases have similar causal pathways (Snow and Seddon, (1999)). Positive 
associations between AMD and cardiovascular risk factors lend support to this proportion (blood pressure, 
plasma cholesterol, and smoking) (Evans, (2001)). The prominent histopathological and clinical lesions in 
AMD involve Bruch’s membrane, a specialized vascular intima separating the photoreceptors and their 
support cells, the retinal pigment epithelium (RPE), from their blood supply. Because these lesions and 
Bruch’s membrane contain abundant lipids, including cholesterol (Haimovici et al., (2001), Curcio et al., 
(2001)), it is possible that AMD and cardiovascular disease share common mechanisms at the level of the 
vessel wall.  
The latest findings (Ebrahimi and Handa, 2011; Charters, 2013) indicates  that AMD is a multifactorial 
disease of the photoreceptor support system, the retinal pigment epithelium (RPE), and Bruch’s membrane 
in the choroid with involvement of lipids and lipoproteins in the formation of AMD lesions. Dr. Curcio 
proposed a unified theory of AMD pathogenesis based on lipid deposition at Retina Subspecialty Day 
during the American Academy of Ophthalmology annual meeting in Chicago ( June,2012). The theory 
hypothesizes that oil red O binding in Bruch’s membrane, which is the single biggest aging change in 
normal eyes, serves as a barrier to delivery of micronutrients to the RPE and photoreceptors and may be a 
source of lipids that can be peroxidized by free radicals into proinflammatory, proangiogenic, and cytotoxic 
compounds. This provides a cleavage plane for neovessels from the choroid growing under the RPE. This 
lipid deposition in Bruch’s membrane may be a manifestation of the systemic process of perifibrous lipid 
deposition and the foundation for atherosclerosis, xanthoma, and lipid keratopathy, she explained. Lipids 
are the biggest component of drusen, especially soft drusen, and are dominated by esterified cholesterol (oil 
red O). Lipoprotein particles accumulate in Bruch’s membrane with aging and form basolinear deposits. 
The RPE secretes apoB and E particles that are retained in Bruch’s membrane; the RPE expresses hallmark 
genes of a lipoprotein secretor and the apolipoproteins are localized to drusen. The lipoproteins come from 
multiple lipid sources; in Bruch’s membrane, the lipoprotein fatty acids resemble those from dietary sources. 
There are now new precursors with potential for clinical intervention, including lipoprotein metabolism and 
modification and regulation of inflammation. This means that new treatments for pharmaceutical and 
dietary modulation of dyslipidemia can be retooled to restore Bruch’s membrane. 
The most commonly used lipid lowering drugs are statins or 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors. Recent experimental evidence suggests that these agents appear to 
display additional cholesterol independent or pleiotropic effects, contributing to prevention and inhibition 
of atherosclerosis. The statins’ vascular pleiotropic effects include improvement of endothelial function, 
slowing the inflammation process, inhibition of the thrombus formation, enhancement of plaque stability 
and decreasing oxidative stress (Wolfovitz, (2005)).  
Statins are widely used in clinical practice because, they are effective and evidence based drugs. The Heart 
Protection Study randomized more than 20,000 patients, and the value of statins in reducing adverse 
cardiovascular events in high–risk patients, including the elderly, women, and even in those with low 
cholesterol levels was beyond doubt (Li, (2005)). As a result, statins are now considered as one of the most 
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powerful classes of agents for the treatment of vascular disease (Li, (2003), Ostadal, (2003)). Statins have a 
strong efficacy record in reducing cholesterol, cardiovascular events, and (in secondary prevention for men 
under age 70, deaths (Baigent et al., 2005; Golomb et al., 2009; Egan and Colman, 2011). 
Statins are rapidly becoming frontline therapy among patients with diabetes mellitus, hypertension, and 
other known vascular risk factors. Statins lower serum lipid levels, and accumulation of lipids in the Bruch 
membrane and drusen is a key pathophysiologic pathway for AMD development (Guymer et al., 2005). 
Statins also appear to have beneficial effects on other AMD pathways such as oxidative damage and 
inflammation (Guymer et al., 2005, 2008). Choroidal neovascular membranes associated with ARMD 
include macrophages (Grossniklaus, 2000), which may respond to statins. The goal of this review is to 
evaluate the effectiveness of these drugs as an alternative therapy in AMD. 
The National Centre for Biotechnology Information (NCBI) at the US National Library of Medicine (NLM) 
was searched using the terms “Statins in age-related macular degeneration”. 
2. Statins and incidence of age-related macular degeneration 
The association between the use of statins and age-related macular degeneration has been evaluated in 
many clinical studies; however the results have been contradictory. Klein et al. (2001) have an evaluated 
the impact of “lipid lowering agents” and Delcourt et al (2001) evaluated “hypocholesterolaemic’’ drugs 
and found no association with early AMD or late AMD. Thus the aggregation of statin and non-statin 
medications, as was probably done in these studies, would bias any association towards the null.  
Smeeth et al. (2005) conducted a population based case control study. Case group consists of 18007 people 
with diagnosed ARMD and control group of 86169 people respectively matched on age, sex, and general 
practice. The crude odds ratio for the association between any recorded exposure to statins and ARMD was 
1.32 (95% CI 1.17 to 1.48), but this reduced to 0.93 (95% CI 0.81 to 1.07, p=0.33) after adjustment for 
consultation rate, smoking, alcohol intake, body mass index, atherosclerotic disease, hyperlipidaemia, heart 
failure, diabetes mellitus, hypertension, use of other cardiovascular drugs, and use of fibrates. The authors 
stated that there was no evidence that the risk varied by dose of statin, duration of use, or that the risk 
varied for individual statins and concluded that in the short and medium term statin use is not associated 
with a decreased risk of AMD, and whether subgroups of patients with specific forms of AMD (particularly 
choroidal neovascularisation) benefit from statin therapy remains a possibility.  
Klein et al. (2007) in the observational analysis of a randomized clinical trial have found that, use of statins 
was not associated with AMD. This study was limited to older females and the results should only be 
considered generalisable to females aged 63 and older. McGwin et al. (2006) evaluated both the use of 
cholesterol-lowering medications as a group and the use of statins specifically with regard to the risk of 
AMD. A case-control study was conducted using data from the Cardiovascular Health Study, a 
population-based prospective study of adults enrolled in 1989 and 1990. The authors stated that no 
association exists between having used cholesterol-lowering medications and AMD. However, there was a 
suggestion that statin use might increase the risk of AMD. The results of this study should be interpreted in 
light of its limitations. Firstly, subjects with ARMD were not identified and not confirmed by a 
standardized comprehensive eye examination and the grading of fundus photographs. This limitation 
prohibits analyses with respect to disease severity and type. Also, without confirmatory diagnostic 
information, there is also the possibility of misclassification with respect to AMD status. Secondly, this 
study aggregated statins and non-statins into the group of cholesterol-lowering medications.  
Data from large population-based studies, including previous analyses from the Blue Mountains and Beaver 
Dam studies, have not found a protective association between statin use and AMD (Klein et al., (2003); van 
Leeuwen et al., (2004)), Kaiserman et al. (2009) also stated that statin use is not reducing the risk for wet 
ARMD. Absence of evidence is not evidence of absence. In another new analysis using data from the 
Beaver Dam Eye Study in Wisconsin, statin use at the 10-year examination was not associated with the 
subsequent incidence of early or late AMD, or progression of AMD at the 15-year examination (Klein et al., 
(2007)). Data from new case-control study confirmed also that use of statins was not associated with newly 
diagnosed exudative AMD. The study had 80% statistical power to detect a protective effect of 0.70, but it 
cannot exclude a smaller effect.  
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Chuo et al. (2007) evaluated the effect of lipid-lowering agents in the development of AMD through a 
meta-analysis of observational studies, estimating the pooled relative risk (RR) for all eight studies, and 
also for seven studies examining the use of statins, for those RR was 0.70 (95% CI, 0.48-1.03). The authors 
concluded that lipid-lowering agents, including statins, do not appear to lower the risk of developing AMD, 
although clinically significant effects cannot be excluded. Hall et al. (2001) reported a significantly lower 
frequency of AMD (defined broadly as all types and severities) among statin users relative to non-users. 
The OR reported in that study was 0.14, 95% CI 0.02-0.83. The limitations of the Hall et al. (2001) have 
been addressed in detail and include the small sample size and the cross sectional designs (van Leeuwen, 
(2001)). Martin-Du Pan RC (2003) confirmed that statins are well tolerated and they could reduce the risk 
of macular degeneration. Data from cohort study of patients with bilaterial large drusen within a multicenter, 
randomized, clinical trial are not consistent with a strong protective effect (risk ratio, ≤ 0.85) of statins on 
the development of advanced AMD among these patients (Maguire et al., (2009)).  
Baghdasarian et al. (2004) in a cross-sectional analysis have found that AMD was less common among 
statin users than nonusers (4% [1/27] vs. 22% [76/352]; p=0.02). Etminan et al. (2008) in the observational 
study have found a slightly higher risk of developing AMD among statin users. Observational studies 
evaluating treatment effects are subject to range a biases, bringing to heterogeneity of findings. 
Drobek-Slowik et al., (2008) in case-control study revealed statin use may be a protective factor against 
AMD. Treatment indication and compliance biases, which refer to distortion of associations resulting from 
known and unknown differences in participant characteristics, prescribed the treatment and the treatment 
actually taken, are difficult to quantify and may also vary in magnitude between the studies. There is 
evidence that the pattern, prescription, and type of statin usage have changed in the last decade. 
Furthermore, there is evidence that not all statins are equally effective for lipid lowering. In a meta-analysis, 
atorvastatin displayed two to four times the potency of simvastatin in reducing total cholesterol levels 
(McCarty, (2001). Thus, it is likely that the type and dosage of evaluated statins are different.  Statins 
could provide some protective effect that is too small to be measured by small studies. 
In the latest largest study conducted by Shalev et al. (2011) investigating  statin use and the risk of age 
related macular degeneration  in large health organization in Israel the crude incidence rate of AMD 
among patients at the lowest quintile of persistence with statins  (7.18 per 1,000) was comparable to that 
of highest persistence quintile ( 7.13 per 1,000). After adjustment for potential confounders, patients in the 
highest quintile of persistence with statins had a hazard ratio of 0.99 (95% Confidence interval: 0.78-1.26) 
for AMD compared with patients in the lowest proportion of days covered (PDC) quintile. In addition to 
age, AMD was found to associate with past smoking, asthma, diabetes and frequent visits to 
ophthalmologists or primary physicians prior to index date.  The authors concluded and agreed with 
previous studies that showes no association berween persistent use of statins and reduced risk of ARMD. A 
Cochrane database review published in March 2012 also did not find sufficient evidence to determine the 
effectiveness and safety of statins for the prevention or delaying the progression of AMD (Gehlbach et al., 
20120, since only two studies met the selection criteria. One trial reported insufficient details to assess the 
risk of bias; the other trial is ongoing. 
Of the completed trial, the analyses of 30 participants did not show a statistically significant difference 
between the simvastatin and the placebo arm in visual acuity at three months of treatment (decimal visual 
acuity 0.21± 0.56 in simvastatin and 0.19± 0.40 in placebo arm) or 45 days after the completion of 
treatment (decimal visual acuity 0.20± 0.50 in simvastatin and 0.19± 0.48 in placebo arm). The lens and 
retina status were unchanged during and after the treatment period for both groups.  In conclusion, statins 
could provide some protective effect that is too small to be measured by small studies, because at the same 
time but in a large prospective study including 38 192 men and 90 874 women during 12 years of follow-up 
Gao et al. (2012) have found that regular use of statins was associated with a modest reduction in Parkinson 
disease risk. Peponis et al. (2010) in a mini review also concluded that there is a need for large scale 
prospective studies with a long follow-up period and accurate assessment of AMD to further explore this 
matter. 
In the latest study examined the role of heme oxygenase-1 as a target and potential mediator of statins in 
cultured human RPE cells Kim et al. (2012) suggested that simvastatin might have some clinical benefits in 
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preventing retinal diseases associated with oxidative stress, such as AMD.  
3. Statins in the treatment of age-related macular degeneration  
The beneficial effect achieved by the treatment of endothelial dysfunction in chronic cardiovascular 
diseases is already evidence belonging to the basic treatment of the disease. Given the fact that the vascular 
system is uniform and consubstantial both physiologically, pathophysiologically and in terms of therapy, 
and that it plays a key role in AMD, endothelial dysfunction should be treated (Fisher, (2008; 2009)).  
McCarty et al. (2001) found that the self-reported use of cholesterol lowering medications was associated 
with a fourfold decreased risk of AMD progression in those who had AMD at baseline; however, because of 
small sample size this finding was not statistically significant. The reliance on self-reported information on 
statin use also represents a potential limitation of this study. McGwin et al. (2003) also reported a 
significant risk reduction for statin users (OR 0.30, 95% CI 0.20 - 0.45) and concluded that subjects with 
ARMD were significantly less likely to have filled a statin prescription. The results of this study should be 
interpreted in light of its strengths and limitations. The primary strength of this study is the use of the 
nested case-control design that allowed for the evaluation of statin use that occurred before AMD diagnosis. 
Given the size of the study base, this study was able to identify a large number of AMD cases (550) and 
matched controls (5500) thereby enhancing the statistical power of the study relative to other studies 
evaluating the relation between statin use and AMD. This study had information on actual filled 
prescriptions and did not rely on self-reported medication use, as have other studies. Although there is no 
information on whether the medications were actually taken, the succession of prescription refills during 
the observation periods among the majority of statin users suggests that these medications were actually 
being taken. Finally, this study population was limited to older males and the results should only be 
considered generalisable to males aged 50 and older.  
McGwin et al. (2005), in the case-control study of 871 AMD cases and 11,717 controls after adjusting for 
the confounding influence of age, gender, and race, revealed a statistically significant relationship between 
AMD and use of cholesterol-lowering medications (OR, 0.79; 95% CI, 0.63-0.99). The results of this study 
add to the growing body of evidence that cholesterol-lowering medications may reduce the risk of 
developing AMD. In the latest analysis of the Blue Mountains Eye Study in Australia, while controlling for 
age and other factors, statin users at baseline and at the five-year follow-up had a 67% lowered risk of 
indistinct soft drusen, a key late AMD precursor lesion, at the 10-year examination. Statin use, however, as 
stated by authors, was not related to the incidence of late AMD or other early AMD signs (Tan et al., (2007). 
This large population-based study as an observational study evaluating treatment effects is subject to a 
range of biases which were discussed earlier.  
Wilson et al. (2004) in a retrospective consecutive case series investigated the relationship between statin 
and aspirin use and the risk of choroidal neovascularization (CNV) in patients with AMD.  
Age-related macular degeneration disease status and time of onset of CNV was compared between patients 
treated or not treated with statins for at least 6 month. Of CNV subjects, 20% used statins, compared with 
38% of dry AMD subjects without geographic atrophy and 33% of controls with geographic atrophy 
(hazard ratio = 0.51, 95% confidence interval (CI) = 0.31-0.86, p=0.01). The general consensus is that 
therapy with statins or aspirin is significantly associated with decreased rates of CNV (Wilsonet al., (2004), 
Girgis, (2004), Gaynes, (2004)). The strength of this study (Wilson et al., (2004)) is the used of main 
outcome measure, represented by angiographically evident CNV, and also the diagnosis, which was based 
on review of fundus photographs and fluorescein angiograms in masked fashion. The latest experimental 
study conducted by Sagara et al. (2007), evaluated the effect of specific statin-pitavastatin on CNV in rats 
and has also advocated the use of pitavastatin in preventing CNV development in AMD patients, based on 
claims that the therapeutic dose of pitavastatin for human hypocholesterolemia effectively suppressed 
experimental CNV in rats. The authors reported that pitavastatin-treated rats had significantly less 
fluorescein leakage, evaluated by masked observers; reduced thickness of CNV and decreased gene 
expression of VEGF. These encouraging results should be confirmed in clinical trials.  
Schmeer et al. (2007) have recently advocated the use of statins in retinal eye diseases, based on their 
anti-apoptotic, anti-proliferative effects, besides lipid-lowering and anti-inflammatory properties. The 
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authors presented evidence for the role of heat shock proteins (Hsps) as target of statin-mediated 
neuroprotective effects in ocular diseases.The general consensus is that a randomized trial of statin use in 
AMD patients is warranted (Klein et al., (2003), McGwin et al., (2003; 2005), Wilson et al., (2004), Chuo 
et al., (2007), Wong and Rogers, (2007)).  
Wong and Rogers (2007) also advocated initiation of a randomized controlled trial. The authors estimated 
the required sample size, described clinically relevant endpoints, and concluded that only 1,704 participants 
are needed for a five-year trial to evaluate the effects of statins on slowing AMD  
Progression by 25% or more (relative risks RR of 0.75 or lower), assuming a cumulative progression rate of 
6% for the placebo group. 
Gehlbach and Hatef (2009) evaluated the effectiveness of statins compared with other treatments, no 
treatment, or placebo in delaying the onset and/or progression of AMD based on findings of randomized 
controlled trials (RCTs). The authors stated that evidence from currently available RCTs was insufficient to 
conclude that statins have any role in preventing or delaying the onset or progression of age-related macular 
degeneration. 
4. Conclusion 
In conclusion, there are potentially multiple biological bases for the protective effect of statins on the risk 
of AMD. With regard to the potential for a lipid lowering effect, cholesterol is a ubiquitous component of 
drusen in normal and AMD eyes. With regard to the potential for pleiotropic effects, many of the same 
processes that occur in the atherosclerotic intima, probably also occur in AMD. Neovascularisation is a 
major complication in both conditions. Therefore, angiogenesis is potential point of statin modulation. 
Taken into account that not all statins are equally effective, the challenge for future laboratory research will 
be to determine the best type and dosage of statins and also to determine which processes are modulated by 
statins in vivo and therefore are primarily responsible for the apparent beneficial effects observed in the 
previous studies. Clearly, further observational studies cannot adequately address many unanswered 
questions. It is time to conduct a randomized controlled trial to provide direct evidence of the effectiveness 
of specific type statin in lowering the incidence and progression of AMD. New intervention as statins usage 
to prevent the development of age-related macular degeneration and its progression remain an important 
strategy to limit the morbidity of this significant public health problem. Improving treatments that reverse, 
prevent, or even delay the onset of AMD would have significant benefit to both the individual and society. 
References 
Baghdasarian SB, Jneid H, Hoogwerf BJ (2004). Association of dyslipidemia and effects of statins on 
nonmacrovascular diseases. Clin Ther. 26(3): 337-351.  
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of 
cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 
randomised trials of statins. Lancet 366: 1267–1278.  
Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp JR.(2005) Age-related macular 
degeneration: economic burden and value-based medicine analysis. Canadian Journal of 
Ophthalmology;40( 3):277–287.  
Centre of Eye Research Australia, Centrally Focused: The Impact of Age-Related Macular Degeneration, 
Access Economics, Melbourne, Australia, 2006.  
Charters  L. AMD pathogenesis based on lipid deposition may answer questions.(2013) Ophthalmology 
Times eReport. 
Chuo JY, Wiens M, Etminan M, Maberley DA (2007). Use of lipid-lowering agents for the prevention of 
age-related macular degeneration: a meta-analysis of observational studies. Ophthalmic Epidemiol. 14(6): 
367-374.  
Curcio CA, Millican CL, Bailey T, Rudolf M (2001). Accumulation of cholesterol with age in human 
Bruch’s membrane. Invest Ophthalmol Vis Sci. 42: 265-274.  
Journal of Pharmacy and Alternative Medicine    www.iiste.org 
ISSN 2222-5668 (Paper) ISSN 2222-4807 (Online)  
Vol. 2, No. 1, 2013 
 
20 
Curcio CA. AMD pathogenesis based on lipid deposition . Retina Subspecialty Day American Academy of 
Ophthalmology annual meeting in Chicago, June 2012. 
Delcourt C, Michel F, Colvez A, Leger CL, Michel F, Papoz L (2001). Associations of cardiovascular 
disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol. 
8: 237-249.  
Drobek-Slowik M, Karczewics D, Safranow K, Jakubowska K, Chlubek DI (2008). Use of statins as a form 
of protection against macular degeneration (AMD). Klin Oczna, 110(1-3): 50-54.  
Ebrahimi KB, Handa JT. Lipids, Lipoproteins, and Age-Related Macular Degeneration (2011). Journal of 
Lipids; Article ID 802059, doi:10.1155/2011/802059 
Egan A, Colman E (2011) Weighing the benefits of high-dose simvastatin against the risk of myopathy. N 
Engl J Med 365: 285–287.  
Etminan M, Brophy JM, Maberley D (2008). Use of statins and angiotensin converting enzyme inhibitors 
(ACE-is) and the risk of age-related degeneration: nested case-control study. Curr. Drug Saf. 3(1):24-26.  
Evans J (2001). Risk factors for age-related macular degeneration. Prog Ret Eye Res. 20: 227-253.  
Fischer T (2008). A new possible strategy of prevention and preventive treatment of age-related macular 
degeneration. Orv Hetil. 149(3): 121-127.  
Fischer T (2009). A new possible strategy of prevention and preventive treatment of age-related macular 
degeneration resting on recent clinical and pathophysiological observations. Orv Hetil. 150(11):503-512.  
Fong DS, Contreras R (2010). Recent statin use and 1-Year incidence of exudative age-related macular 
degeneration. Am J. Ophthalnol. 149(6): 955-958. 
Gao X,. Simon KC, Schwarzschild MA., Ascherio A (2012) Prospective Study of Statin Use and Risk of 
Parkinson Disease. Arch Neurol. 2012;69(3):380-384. 
Gaynes BI (2004). Statin and aspirin therapy are associated with decreased rates of choroidal 
neovascularization among age-related macular degeneration patients. Am J Ophthalmol. 138(6): 1089.  
Gehlbach P, Li T, Hatef E (2009).  Statins for age-related macular degeneration. Cochrane Database Syst 
Rev. (3):CD006927  
Gehlbach P, Li T, Hatef E (2012). Cochrane Eyes and Vision Group. ed. "Statins for age-related macular 
degeneration". Cochrane Database Syst Rev 3: CD006927. doi:10.1002/14651858.CD006927.pub3. PMID 
22419318. 
Girgis RA, McKee HD (2004). Statin and aspirin therapy are associated with decreased rates of choroidal 
neovascularization among patients with age-related macular degeneration. Am J  
Ophthalmol. 138(4): 697.  
Golomb BA, Parrish J, Broadwin JA (2009) Statins and mortality. On the Risk 25: 66–71.   
Grossniklaus HE, Cingle KA, Yoon YD (2000). Correlation of histologic 2-dimensional reconstructional 
and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related 
maculopathy. Arch Ophthalmol. 118: 625-629.  
Guymer RH, Chiu AW, Lim L, Lim LL, Baird PN, et al. (2005). HMG CoA reductase inhibitors (statins): 
do they have a role in age-related macular degeneration? Surv Ophthalmol; 50(2): 194-206.  
Guymer RH, Dimitrov PN, Varsamidis M, Lim LL, Baird PN, et al (2008). Can HMG Co-A reductase 
inhibitors (statins) slow the progression of age-related macular degeneration? The age-related maculopathy 
statin study (ARMSS). Clin. Interv. Aging. 3(3):581-593.  
Haimovici R, Gantz DL, Rumelt S, et al. (2001). The lipid composition of drusen, Bruch’s membrane, and 
sclera by hot stage polarizing microscopy. Invest Ophthalmol Vis Sci. 42: 1592-1599.  
Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN (2001). Risk of macular degeneration in users of 
statins: cross sectional study. BMJ. 323(7309): 375-376.  
Journal of Pharmacy and Alternative Medicine    www.iiste.org 
ISSN 2222-5668 (Paper) ISSN 2222-4807 (Online)  
Vol. 2, No. 1, 2013 
 
21 
Kaiserman N, Vinker S, Kaiserman I. (2009). Statins do not decrease the risk for wet age-related macular 
degeneration. Curr.Eye Res. 34(4): 304-310.  
Kim KJ, Kim KS, Kim NR, Chin HS.(2012) Effects of Simvastatin on the expression of Heme 
Oxygenase-1 in Human Retinal Pigment Epithelial Cells. Invest Ophthalmol Vis Sci. 21;53(10):6456-6464. 
Klein R, Deng Y, Klein BE (2007). Cardiovascular disease, its risk factors and treatment, and age-related 
macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol . 43(3): 
473-483.  
Klein R, Klein BE, Jensen SC, Cruickshanks KJ, Lee KE, et al (2001). Medication use and the 5-year 
incidence of early age-related maculopathy. Arch Ophthalmol. 119: 1354-1359.  
Klein R, Klein BE, Tomany SC (2003). Relation of statin use to the 5-year incidence and progression of 
age-related maculopathy. Arch Ophthalmol. 121(8): 1151-1155.  
Klein R, Knudston MD, Klein BE (2007). Statin use and the live-year incidence and progression of 
age-related macular degeneration. Am.J.Ophthalmol. 144(1):1-6.  
Leeuwen R, Vingerling JR, de Jong PT (2001). Risk of macular degeneration with statin use should be 
interpreted with caution. BMJ. 323(7324): 1308.  
Leeuwen RV, Tomany SC, Wang JJ (2004). Is medication use associated with the incidence of early 
age-related maculopathy? Pooled findings from 3 continents. Ophthalmol. 111:1169-1175.  
Li JJ (2003). Rapid effects on lipid profile and C-reactive protein by simvastatin in patients with 
hypercholesterolemia. Clin Cardiol. 26: 472-476.  
Li JJ, Hu SS (2005). Early, Intensive and long-term statin therapy in acute coronary syndrome: focus on 
anti-inflammatory mechanisms. Vascular Disease Prevention. 2(3): 181-186.  
Lim LS,  Mitchell P,   Seddon JM,   Holz FG,  Wong TY. (2012) Age-related macular degeneration. 
The Lancet,  379, Issue 9827, 1728 – 1738. 
Maquire MG, Ying GS, McCannel CA, Lin C, Dai Y (2009). Statin use and the incidence of advanced 
age-related macular degeneration in the complications of age-related macular degeneration prevention trial 
(CAPT). Ophthalmology. 138(5):698-704.  
Martin-Du Pan RC (2003). Prevention of cardiovascular and degenerative diseases: I. Aspirin, statins, or 
vitamins? Rev Med Suisse Romande. 123(3): 175-181.  
Mc Carty CA, Mukesh BN, Guymer RH (2001). Cholesterol-lowering medications reduce the risk of 
age-related maculopathy progression. MJA. 175: 340.  
McGwin G Jr, Owsley C, Curcio CA, Crain RJ (2003). The association between statin use and age related 
maculopathy. Br J Ophthalmol. 87(9): 1121-1125.  
McGwin Jr G, Xie A, Owsley C (2005). The use of cholesterol-lowering medications and age-related 
macular degeneration. Ophthalmol. 112(3): 488-494.  
McGwin JrG, Modjarrad K, Hall TA (2006). 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
and the presence of age-related macular degeneration in the Cardiovascular Health Study. Arch Ophthalmol. 
124(1): 33-37.  
Mukesh BN, Dimitrov PN, Leikin S. (2004) Five-year incidence of age-related maculopathy: the visual 
impairment project,” Ophthalmology, 111(6), 1176–1182. 
Ostadal P, Alan D, Hajek P (2003). The effect of early treatment by cerivastatin on the serum level of 
C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave 
myocardial infarction. Mol Cell Biochem. 246: 45-50.  
Peponis V, Chalkiadakis SE, Bonovas S, Sitaras NM.(2010) The controversy over the association between 
statins use and progression of age-related macular degeneration: a mini review. Clinical 
Ophthalmology,4 ;865 – 869.DOI: http://dx.doi.org/10.2147/OPTH.S12869 
Journal of Pharmacy and Alternative Medicine    www.iiste.org 
ISSN 2222-5668 (Paper) ISSN 2222-4807 (Online)  
Vol. 2, No. 1, 2013 
 
22 
Prevent Blindness America and the National Eye Institute  report “Vision Problems in the U.S”, 2012. 
Ryan S, Retina, vol. 1, Elsevier Health Sciences, 4th edition, 2006 
Sagara N, Kawaji T, Takano A (2007). Effect of pitavastatin on experimental choroidal neovascularization 
in rats. Exp Eye Res. 84(6): 1074-1080.  
Schmeer C, Kretz A, Isenmann S (2007). Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors for the treatment of retinal and eye diseases. CNS Neurol. Disord Drug Targets. 6(4): 
282-287.  
Shalev V, Sror M, Goldshtein I, Kokia E, Chodick G (2011). Statin use and the risk of age related macular 
degeneration in a large health organization in Israel. Ophthalmic Epidemiol.18(2):83-90  
Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE (2005). A case control study of age related 
macular degeneration and use of statins. Br J Ophthalmol . 89(9): 1171-1175.  
Snow KK, Seddon JM (1999). Do age-related macular degeneration and cardiovascular disease share 
common antecedents? Ophthalmic Epidemiol. 6: 125-143.  
Tan JS, Mitchell P, Rochtchina E, Wang JJ (2070). Statins and the long-term risk of incident age-related 
macular degeneration: the Blue Mountains Eye Study. Am J Ophthalmol: 143(4): 685-687.  
Wilson HL, Schwartz DM, Bhatt HR (2004). Statin and aspirin therapy are associated with decreased rates 
of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol. 
137(4): 615-624.  
Wolfovitz E (2005). The pleiotropic effects of statins. Harefuah; 144(8): 577-582, 597.  
Wong TY, Rogers SL (2007). Statins and age-related macular degeneration: time for a randomized 
controlled trial? Am J Ophthalmol. 144(1): 117-119. 
This academic article was published by The International Institute for Science, 
Technology and Education (IISTE).  The IISTE is a pioneer in the Open Access 
Publishing service based in the U.S. and Europe.  The aim of the institute is 
Accelerating Global Knowledge Sharing. 
 
More information about the publisher can be found in the IISTE’s homepage:  
http://www.iiste.org 
 
CALL FOR PAPERS 
The IISTE is currently hosting more than 30 peer-reviewed academic journals and 
collaborating with academic institutions around the world.  There’s no deadline for 
submission.  Prospective authors of IISTE journals can find the submission 
instruction on the following page: http://www.iiste.org/Journals/ 
The IISTE editorial team promises to the review and publish all the qualified 
submissions in a fast manner. All the journals articles are available online to the 
readers all over the world without financial, legal, or technical barriers other than 
those inseparable from gaining access to the internet itself. Printed version of the 
journals is also available upon request of readers and authors.  
IISTE Knowledge Sharing Partners 
EBSCO, Index Copernicus, Ulrich's Periodicals Directory, JournalTOCS, PKP Open 
Archives Harvester, Bielefeld Academic Search Engine, Elektronische 
Zeitschriftenbibliothek EZB, Open J-Gate, OCLC WorldCat, Universe Digtial 
Library , NewJour, Google Scholar 
 
 
